Abstract

The immortalized human ReNcell VM cell line represents a reproducible and easy-to-propagate cell culture system for studying the differentiation of neural progenitors. To better characterize the starting line and its subsequent differentiation, we assessed protein and phospho-protein levels and cell morphology over a 15-day period during which ReNcell progenitors differentiated into neurons, astrocytes and oligodendrocytes. Five of the resulting datasets measured protein levels or states of phosphorylation based on tandem-mass-tag (TMT) mass spectrometry and four datasets characterized cellular phenotypes using high-content microscopy. Proteomic analysis revealed reproducible changes in pathways responsible for cytoskeletal rearrangement, cell phase transitions, neuronal migration, glial differentiation, neurotrophic signalling and extracellular matrix regulation. Proteomic and imaging data revealed accelerated differentiation in cells treated with the poly-selective CDK and GSK3 inhibitor kenpaullone or the HMG-CoA reductase inhibitor mevastatin, both of which have previously been reported to promote neural differentiation. These data provide in-depth information on the ReNcell progenitor state and on neural differentiation in the presence and absence of drugs, setting the stage for functional studies.

Design Type(s)

cell differentiation design • proteomic profiling design • observation design • replicate design • factorial design

Measurement Type(s)

proteomic profiling • cell differentiation

Technology Type(s)

liquid chromatography-tandem mass spectrometry • fast live imaging

Factor Type(s)

Stage • drug • passage number • biological replicate • technical replicate • primary antibody

Sample Characteristic(s)

Homo sapiens • immortal cell line cell

Machine-accessible metadata file describing the reported data (ISA-Tab format)

Details

Title
A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line
Author
Song Yuyu 1   VIAFID ORCID Logo  ; Subramanian Kartik 2   VIAFID ORCID Logo  ; Berberich, Matthew J 2   VIAFID ORCID Logo  ; Rodriguez, Steven 3   VIAFID ORCID Logo  ; Latorre, Isabel J 2   VIAFID ORCID Logo  ; Luria, Catherine M 2   VIAFID ORCID Logo  ; Everley, Robert 4   VIAFID ORCID Logo  ; Albers, Mark W 3   VIAFID ORCID Logo  ; Mitchison, Timothy J 1   VIAFID ORCID Logo  ; Sorger, Peter K 2   VIAFID ORCID Logo 

 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital, Department of Neurology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Cell Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Publication year
2019
Publication date
Mar 2019
Publisher
Nature Publishing Group
e-ISSN
20524463
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2357412303
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.